November 17, 1950
`
`Youngstown, Ohio
`
`Married
`Marilyn Goske Rudick, M.D.
`
`Brian Rudick (11/17/81)
`Jamie Rudick (9/29/84)
`
`
`
`
`B.S. Ohio University, Athens, Ohio
`M.D. Case Western Reserve University
`
`School of Medicine, Cleveland, Ohio
`
`Curriculum Vitae
`
`RICHARD A. RUDICK, M.D.
`May 16, 2016
`
`
`
`
`
`
`
`
`
`Date of Birth:
`
`Place of Birth:
`
`Marital Status:
`
`
`
`Children:
`
`
`
`Education:
`
`
`
`
`
`
`Positions:
`
`Resident in Medicine
`
`University of Connecticut School of Medicine
`
`Farmington, Connecticut 06032
`Resident in Neurology
`
`Strong Memorial Hospital
`
`University of Rochester School of Medicine
`
`Rochester, New York 14642
`Chief Resident Neurology
`
`Strong Memorial Hospital
`
`University of Rochester School of Medicine
`Instructor in Neurology
`
`University of Rochester School of Medicine
`Postdoctoral Research Fellow
` Center for Brain Research
`
`University of Rochester School of Medicine
`Associate Medical Director
`
`Rochester Area Multiple Sclerosis Society
`
`Rochester, New York
`Assistant Professor of Neurology
`
`University of Rochester School of Medicine
`Associate Professor of Neurology
`
`University of Rochester School of Medicine
`Associate Neurologist
`
`Strong Memorial Hospital
`
`
`
`1971
`1975
`
`1975-1977
`
`1977-1980
`
`1979-1980
`
`1979-1980
`
`1979-1980
`
`1979-1986
`
`1980-1986
`
`1986-1987
`
`1980-1987
`
`Page 1 of 70
`
`Biogen Exhibit 2045
`Coalition v. Biogen
`IPR2015-01993
`
`

`

`Curriculum Vitae
`Richard A. Rudick, M.D.
`
`University of Rochester School of Medicine
`
`Adjunct Associate Professor of Neurology
`
`University of Rochester School of Medicine
`Chairman, Division of Clinical Research, Cleveland Clinic
`Director, Mellen Center for Multiple Sclerosis Treatment & Research,
` Cleveland Clinic
`Hazel Prior Hostetler Professor of Neurology, Cleveland Clinic 1995-2014
`Professor, Department of Medicine, Primary Appointment, in the
`2003-2014
` Cleveland Clinic Lerner College of Medicine (CCLCM)
`Professor, Department of General Medical Sciences, Secondary
` Center for Clinical Investigation in the Case School of Medicine
`Vice-Chairman, Research and Development, Neurological Institute,
` Cleveland Clinic
`University Graduate Faculty, Cleveland State University
`Vice-President, Development Sciences, Value Based Medicine
`
`Biogen Idec, Boston, MA
`
`Board Certification and Licensure:
`
`National Board of Medical Examiners, Diplomate
`American Board of Internal Medicine, Certified
`American Board of Psychiatry and Neurology, Certified
`Licensed, State of New York, #136732
`Licensed, State of Ohio, License #54570
`License, State of Nevada, License #13371
`
`Professional Societies:
`
`Alpha Omega Alpha Honorary Medical Society
`American Academy of Neurology, Fellow
`New York Academy of Sciences, Member
`Society for Experimental Neuropathology, Member
`American College of Physicians, Fellow
`American Neurological Association, Member
`American Society of Neurorehabilitation, Certified Member
`American Society for Experimental Neuro Therapeutics (ASENT), Member
`American Association for Advancement of Science
`American Association for the Advancement of Science, Fellow
`Association of American Physicians, Member
`Society for Clinical and Translational Science (SCTS), Member
`
`Editorial Experience:
`
`Archives of Neurology, Assistant Editor
`
`Archives of Neurology, Member, Editorial Board
`Seminars in Neurology, Guest Editor, Disorders of Myelin
`Cleveland Clinic Neuroscience Pathways newsletter, Medical Editor
`
`1976
`September 1978
`November 1981
`1978
`1986
`December 2009
`
`
`
`
`
`1982-1996
`1983-1996
`1985
`1992-1997
`
`Page 2
`
`
`
`1987-1995
`
`2001-2007
`1987-2014
`
`2006-2014
`
`2007-2014
`
`2013-2018
`2014-
`
`1974
`1981
`1983
`1990
`1992
`1992
`1993
`1998
`2001
`2006
`2007
`2009
`
`Page 2 of 70
`
`

`

`Curriculum Vitae
`Richard A. Rudick, M.D.
`
`Annals of Neurology, The Journal of the American Medical Association
`
`(JAMA), Archives of Neurology, The Lancet, New England Journal
` Medicine, Neurology, Journal of Neuroimmunology, Ad-Hoc Reviewer
`Multiple Sclerosis - Clinical Issues, Editorial Board
`Lancet Neurology, Editorial Board
`Therapy published by Future Medicine, U.S. Guest Editor,
` Multiple Sclerosis Special Focus Issue
`New Frontiers in Multiple Sclerosis: Impact of Disease-Modifying
`Therapies on Nontraditional measures of Disease Activity;
`Guest Editor and Author, Neurology Supplement
`Neurotherapeutics, Editorial Board
`
`Honors and Awards:
`
`Valedictorian, The Rayen School, Ranked 1/273
`Borden Freshman Prize for The Outstanding Student
` Ohio University, Athens, Ohio
`Josephus Tucker Ullom Premedic Award (Outstanding Premed
`
`Student, Ohio University)
`Honors College, Ohio University
`Alpha Omega Alpha Honors Medical Society, CWRU School of
` Medicine (Elected as Junior Student)
`Teacher-Investigator Development Award
`
`(KO7NS00791) NINCDS "Humoral Immunity in MS"
`Outstanding Alumnus of the Year Award
` Ohio University College of Arts and Sciences
`Bruce Hubbard Stewart Award for Humanistic Medicine
` Cleveland Clinic Foundation
`Hazel Prior Hostetler Professor of Neurology
` Cleveland Clinic Foundation
`Alumnus of the Year Award, Department of Neurology
`
`University of Rochester
`Innovation Award for Brain Parenchymal Fraction Software from
`
`Enterprise Development, Inc.
`Arnold and Geri King Lifetime Achievement Award from
` National Multiple Sclerosis Society
`Health Care Professional Hall of Fame Award from
` National Multiple Sclerosis Society
`Distinguished Alumnus Award
` Case Western Reserve University
`Excellence in Health Science Innovation Award (first recipient)
` Case Western Reserve University
`32nd TS Srinivasan Oration Award
`
`TS Srinivasan Centre for Clinical Neurosciences-VHS Hospital
` Chennai, India
`Alfred and Norma Lerner Humanitarian Award
` Cleveland Clinic’s most prestigious physician honor - received 10/17/2012
`
`Page 3
`
`
`
`1986-Present
`
`1992-2010
`2004-2012
`2008
`
`2010-2012
`
`2011-2014
`
`1968
`1969
`
`1971
`
`1968-1971
`1974
`
`1983-1988
`
`1994
`
`1995
`
`1996
`
` 1998
`
`2000
`
` 2002
`
`2003
`
`2010
`
`2011
`
`2012
`
`2012
`
`Page 3 of 70
`
`

`

`Curriculum Vitae
`Richard A. Rudick, M.D.
`
`
`National Grant Review:
`NIH - General Clinical Research Center site visit
`
`University of Alabama
`NIH - NINCDS Program B Ad Hoc Reviewer, University of
`
`Pennsylvania, Wistar Institute, Philadelphia, PA
`National Multiple Sclerosis Society, Committee A
` Member
` Chairman
`NIH – General Clinical Research Center site visit
` Massachusetts General Hospital
`NIH – NIAID Ad Hoc member study section on Autoimmunity
` Centers of Excellence
`NIH, NINDS, Patient Monitoring Safety Board, Chairman
`NIH – Patient Monitoring Board for NINDS (Chair)
`
`Committees & Advisory Boards
`
`External Committees:
`International Federation of Multiple Sclerosis Societies
` Medical Advisory Board
`National Multiple Sclerosis Society, National Clinical Advisory Board,
`
`(formerly known as: Medical Advisory Board)
`National Institutes of Health (NIH) - Member, National Center
`
`for Research Resources (NCRR)
` National Advisory Research Resources Council (NARRC)
`Case Comprehensive Cancer Center –
`
`Internal Advisory Board for Specialized Centers of Interdisciplinary
`
`Research (SCOR)
`
`Institutional Advisory Board (IAB)
`National Institutes of Health (NIH), Office of Portfolio Analysis and
`
`Strategic Initiatives (OPASI), Member, Council of Councils
`National Institutes of Health (NIH), Office of Portfolio Analysis
` and Strategic Initiatives (OPASI), Council of Councils,
`
`Subcommittee on Resource Development and Analysis, Chair.
`National Institutes of Health (NIH) - Member, National Center for
`
`Research Resources (NCRR), Member, IDeA Eligibility Working
` Group (IEWG)
`Biogen Idec, SURPASS Advisory Board
`National Multiple Sclerosis Society, National Clinical Advisory Board,
`
`Executive Committee (formerly known as: Medical Advisory Board,
`
`Executive Committee)
`National Institutes of Health (NIH) - CombiRx Advisory Committee
`National Multiple Sclerosis Society, Research Programs Advisor
` Committee (RPAC)
`National Multiple Sclerosis Society, Research Programs Advisor
` Committee (RPAC)-Chair
`
`Page 4
`
`
`
`1985
`
` 1987
`
`1990-1992
`1992-1995
`2002
`
`2003
`
`1997-1998
`1998-2000
`
`1993-1998
`
`2005-2012
`
`2006-2010
`
`2006
` 2006
`2007-2010
`
`2007-2010
`
`2008-2010
`
`2009-2011
`2009-2012
`
`
`2004-Present
`2006-Present
`
`2009-2012
`
`Page 4 of 70
`
`

`

`Curriculum Vitae
`Richard A. Rudick, M.D.
`
`American Academy of Neurology, John J. Dystel Prize for
` Multiple Sclerosis Research Subcommittee
`American Society for Experimental Neurotherapeutics (ASENT),
`
`Rudick on Board of Directors
`American Society for Experimental Neurotherapeutics (ASENT),
`
`Strategic Plan Subcommittee for the Board, Rudick Member
`National Institutes of Health (NIH), NINDS MS CDE Working Group:
` NINDS=National Institute of Neurological Disorders and Stroke;
` CDE = Common Data Elements; Member
`National Institutes of Health (NIH), NINDS MS CDE Oversight Committee;
`
`Rudick Member
`National Multiple Sclerosis Society, Fast Forward President Advisory
`
`Search Committee
`National Multiple Sclerosis Society, MSFC Task Force; Chair
`
`(MSFC=Multiple Sclerosis Functional Composite)
`National Multiple Sclerosis Society, Critical Path Institute; Multiple
`
`Sclerosis Outcomes Assessment Task Force, Co-Director
`Multiple Sclerosis International Federation (MSIF); Executive Committee
`
`of the International Medical and Scientific Board (IMSB)
`
`
`Internal - Cleveland Clinic Appointed Committees and Subcommittees:
` Academic Council
` Campaign Executive Board (Medical Director)
` CCHS Leadership Team
` Committee for Responsible Research Conduct (Chair)
` Division of Clinical Research Executive Committee (Chair)
` Medical Executive Committee (MEC)
`
`Pediatric Neurology and Neurosurgery Review Committee (Chair)
` Dept. of Psychiatry & Psychology Chair Review Committee (Member)
` NI Neuroepidemiologist Search Committee (Member)
`
`Psychiatry Resident Research Track Selection Committee
`
`Research Strategic Council
`
`Internal – Other Institutional Support Activities:
` GCRC (General Clinical Research) Executive Committee Meeting
`
`Intellectual Properties (IP) Contract Review Sub-Committee
` Neurosciences Leadership Board (Physician Chair)
` MCRTP (K12) -
`
` Multidisciplinary Advisory Committee/MAC (Chair)
`
`
`Steering Committee Meeting / Member
`
`
`Leadership Committee (Chair)
` Neurological Institute (NI) Definitions, Roles, Clarity
`
` Committee (Chair)
`
`Board of Trustees Development Committee, Advisor
`
`Board of Trustees Research and Education Committee, Advisor
` Cleveland Clinic Lou Ruvo Center for Brain Health (CCLRCBH)
`
`
`Research Committee (Chair)
`
`
`2007-2013
`
`2010-Present
`
`2011-Present
`
`2010-Present
`
`
`2013-Present
`
`2011-2012
`
`2011-2012
`
`2012-Present
`2013-Present
`
`2003
`2006
`2004-2007
`2002-2007
`2002-2007
`2003-2007
`2008-2009
`2009
`2010
`2009-2010
`2010-2014
`
`2002-2007
`2002-2006
`2003
`2004
`2004
`2004
`2005
`2006
`
`2006-2007
`2006-2007
`2009-2010
`
`Page 5
`
`Page 5 of 70
`
`

`

`Internal Advisory Board, T32 Training Grant in Hematology, Member
`
`
`2011
`
`
`
`Funding
`
`
`
`Term
`
`N/A 1979-1980
`
`$9,000 1981-1982
`
`$105,250 1981-1984
`
`$10,000 1981-1982
`
`$20,000 1982-1983
`
`$187,500 1983-1988
`
`$71,263 1983-1985
`
`$9,813 1984-1985
`
`$170,814 1984-1987
`
`$48,000 1985-1989
`
`$7,500 1985-1986
`
`$85,882 1987-1989
`
`$169,000 1988-1991
`
`Curriculum Vitae
`Richard A. Rudick, M.D.
`
`
`
`Research Grants:
`
`
`Grant
`
`Post-Doctoral Fellowship; Center for Brain Research;
`University of Rochester; (PHS NIMH Training Grant) Sponsor,
`Robert M. Herndon, M.D.
`
`Basic Research Support Grant, ‘CSF Physiology in Murine
`Immune Complex Disease’ University of Rochester
`
`Kroc Foundation, ‘Immunologic and Immuno-Electron
`Microscopic Findings in MS’ Co-Investigator; PI-Robert M.
`Herndon, M.D.
`
`Buswell Fellowship, University of Rochester School of
`Medicine
`
`Diamond Shamrock Corporation, ‘High Resolution Electron
`Microscopy of Ferritin-Labeled Immune Complexes: A New
`Method for Immune Complex Characterization.’
`
`Teacher-Investigator Development Award NIH - NINCDS
`K07NS00791, ‘Humoral Immunity in MS’
`
`Lorex Pharmaceuticals, ‘Progabide-Treatment of Spasticity
`in MS: A Double-Blind, Placebo-Controlled Trial.’
`
`Basic Research Support Grant, ‘Immune Complex
`Characterization in Multiple Sclerosis’ University of
`Rochester.
`
`US PHS R01NS20303, ‘Humoral Immunity in Multiple
`Sclerosis.’
`
`Lorex Pharmaceuticals: ‘Progabide Treatment for Spasticity
`in MS: An Open-Label Follow-Up Trial.’
`
`University of Rochester CRC, ‘Pregnancy and Multiple
`Sclerosis’ University of Rochester. Co-Investigator; PI-Kathy
`Birk, M.D.
`
`Cleveland Clinic Foundation RPC, ‘Neuroimmunology of
`Multiple Sclerosis (Start-up Funds)’
`
`National Multiple Sclerosis Society, ‘Immune Effects of
`Interferon in Multiple Sclerosis’
`
`Page 6
`
`Page 6 of 70
`
`

`

`Curriculum Vitae
`Richard A. Rudick, M.D.
`
`
`US PHS R01NS20303, ‘Humoral Immunity in Multiple
`Sclerosis.’
`
`National Multiple Sclerosis Society, ‘Description of the
`Caregivers of MS Persons’
`
`National Multiple Sclerosis Society, ‘Low Dose Oral
`Methotrexate in Chronic Progressive MS’ Co-Investigator;
`PI-Donald Goodkin, M.D.
`
`National Multiple Sclerosis Society, ‘Evaluating Selected
`Monitoring Techniques in MS Clinical Trials’ Co-Investigator;
`PI-Donald Goodkin, M.D.
`NIH R01NS26321, ‘IM Recombinant Beta Interferon as
`Treatment for MS’ Co-Investigator; PI-Lawrence Jacobs,
`M.D.
`
`Abbott Laboratories, ‘Zileuton for Multiple Sclerosis’
`
`National Multiple Sclerosis Society, ‘Immune Effects of
`Interferon Beta in Multiple Sclerosis Patients’
`
`Biogen, Inc., ‘Immune Effects of Interferon Beta in Multiple
`Sclerosis Patients’
`National Multiple Sclerosis Society, ‘Intervention Strategies
`For MS-Related Cognitive Dysfunction’, Co-Investigator; PI-
`Jill Fischer
`Biogen, Inc., C94-801, ‘An Open-Label Study of Avonex In
`Patients With Multiple Sclerosis’, Principal Investigator
`National Multiple Sclerosis Society, ‘Interleukin 10 Expression
`In Multiple Sclerosis’, Principal Investigator
`National Multiple Sclerosis Society, ‘Monitoring Brain
`Atrophy During The Course of Multiple Sclerosis’, Principal
`Investigator
`National Institutes of Health (P01 NS38667-01A1) ‘Monitoring
`Brain Atrophy During The Course of Multiple Sclerosis. ’
`Project 3 in Program Project ‘Pathogenic Mechanisms In
`Multiple Sclerosis’, Project Director; PI-Richard Ransohoff
`National Institutes of Health (P01 NS38667-01A1) Tissue
`Acquisition & Characterization, Biostatistics, Administration
`Core for Program Project ‘Pathogenic Mechanisms In
`Multiple Sclerosis’, Project Director; PI-Richard Ransohoff
`
`Page 7
`
`
`$200,000 1988-1991
`
`$19,700 1989-1990
`
`$216,892 1989-1992
`
`$118,852 1989-1990
`
`$4,200,000 1990-1994
`
`$36,225 1992-1993
`
`$193,605 1993-1997
`
`$70,000 1993-1995
`
`$257,978 1995-1998
`
`$624,900 1994-2001
`
`$253,323 1996-2000
`
`$515,092 1999-2002
`
`$1,303,967 1999-2004
`
`$533,579 1999-2004
`
`Page 7 of 70
`
`

`

`Curriculum Vitae
`Richard A. Rudick, M.D_
`
`Immunex, ‘Immunologic Effects of mitoxantrone in Multiple
`Sclerosis’, Co-Investigator; Pl-Jeffrey Cohen
`
`National Institutes of Health (C06-RROI 8955) NCRR
`
`Construction Grant, Principal Investigator
`
`National Institutes of Health (I POI NS 38667) Project 4,
`
`‘Biomarkers of the therapeutic response to Interferon in
`MS‘, Project Director: Pl-Richard Ransohoff
`
`$1 80,000
`
`2000-2002
`
`$1 ,000,000
`
`2003-2005
`
`$1,106,015
`
`2004-2009
`
`National Multiple Sclerosis Society RG 3604A6/ I ‘Biomarkers
`of the therapeutic response to Interferon in MS’, Principal
`
`$295,108
`
`2004-2007
`
`Investigator
`
`National Institutes of Health (MOI-RROI8390 ) General
`Clinical Research Center at the Cleveland Clinic
`
`Foundation, Principal Investigator
`
`National Institutes of Health (K12) Case/Cleveland Clinic
`Research Training Program, Principal Investigator
`
`$17,000,000
`
`2003-2007
`
`1: Whole
`amount
`
`folded into
`
`CTSA
`
`Note:
`
`Ended
`
`09/ I 6/2007
`
`$14,080,161
`
`2004-2007
`
`it Whole
`amount
`
`folded into
`
`CTSA
`
`Note:
`
`Ended
`
`09/ I 6/2007
`
`Case Western Reserve University/Cleveland Clinic CTSA.
`
`$64,000,000
`
`2007-201 2
`
`Co-Principal Investigator (Principal Investigator: Pamela
`Davis, MD, PhD)
`
`Case Western Reserve University/Cleveland Clinic CTSA.
`
`$64,600,000
`
`2012-201 7
`
`Co-Principal Investigator (Principal Investigator: Pamela
`Davis, MD, PhD)
`
`National Institutes of Health (5P50NSO38667-I 5), Cleveland
`Clinic, Case Western Reserve University, Cellular and
`
`Molecular Mechanisms of Cortical Remyelination in MS
`Patients, Co-investigator? Principal Investigator: Bruce
`
`$1,013,105
`
`2010-2015
`
`Trapp, MD
`
`Mentoring:
`
`Mentor: Richard Rudick, M.D.
`
`Page 8 of 70
`
`Page 8
`
`

`

`Curriculum Vitae
`Richard A. Rudick, M.D.
`
`Names of
`
`Mentees
`
`Training
`Period
`
`(Status while
`in Trainin 9
`
`Training Support
`
`Current Position
`
`Vincent
`
`7/88—6/93
`
`Weaver Neuroscience
`
`Staff
`
`Tuohy, MD
`
`Junior Faculty
`
`Deborah
`
`Miller, PhD
`
`Junior Faculty
`
`R. Philip
`Kinkel, MD
`
`Postdoctoral
`
`Fellow
`
`Eliza beth
`
`Fisher, PhD
`
`Postdoctoral
`
`Fellow
`
`Bianca
`
`Guttman, MD
`
`Postdoctoral
`
`Fellow
`
`Robert Fox,
`MD
`
`Postdoctoral
`
`Fellow
`
`Junior
`
`Faculty
`
`7/03-
`
`present
`
`Scholarship (Junior Faculty
`
`Award) From National MS
`
`Professor of Molecular Medicine,
`CCLCM
`
`Society
`
`7/88-7/92
`
`PhD Candidate, Mandel
`
`Staff Member, Department of
`
`School of Applied Social
`Sciences, Case Western
`
`Reserve University
`
`Neurology (Mellen Center for MS
`Treatment and Research)
`Cleveland Clinic Foundation
`
`7/90-7]92
`
`National Multiple Sclerosis
`
`Society postdoctoral
`
`fellowship
`
`Assistant Professor of Neurology,
`Harvard Medical School
`
`9/95-8/97
`
`Fellowship supported by
`the Potiker Foundation
`and the Whitaker
`
`Foundation
`
`Associate Professor, Molecular
`
`Medicine, CCLCM
`
`7/94-7/97
`
`Postdoctoral fellowship,
`Cleveland Clinic
`
`Associate Professor of
`
`Neurology, University of Buffalo
`
`7/OI-7/03
`
`Supported by
`
`Postdoctoral Fellowship
`
`Associate Professor, , Dept. of
`Medicine, CCLCM:
`
`National Multiple Sclerosis
`
`Staff, Cleveland Clinic
`
`Society
`
`K23 Award, NINDS
`
`Medical Director, Mellen
`Center, Cleveland Clinic
`
`Ruth Ann
`
`Marrie, MD,
`PhD
`
`Postdoctoral
`Fellow
`
`Junior Faculty
`
`7/Ol-7/04
`
`Postdoctoral Fellowship
`
`Ruth Ann Marrie, MD, PhD,
`
`National Multiple Sclerosis
`Society
`
`FRCP(C)
`Assistant Professor of Medicine &
`
`7/05-7/O7
`
`K12 Award, NIH Roadmap
`
`Multidisciplinary Clinical
`Research Scholar Program
`
`Community Health Sciences
`
`Health Sciences Centre,
`
`Winnipeg, MB, Canada
`R3A IR9
`
`Page 9 of 70
`
`Page 9
`
`

`

`Curriculum Vitae
`Richard A. Rudick, M.D.
`
`
`7/03-7/06
`
`Postdoctoral Fellowship
`National Multiple Sclerosis
`Society
`
`
`Assistant Professor of Neurology,
`University of Virginia
`
`7/07- 7/08 K12 Award, NIH Roadmap
`Multidisciplinary Clinical
`Research Scholar Program
`
`7/2010 –
`Present
`
`KL2 Award, NIH Roadmap
`Multidisciplinary Clinical
`Research Scholar Program
`
`Associate Professor of Clinical
`Ophthalmology
`University of California San
`Francisco
`
`Associate Professor, Dept. of
`Medicine, CCLCM
`
`
`7/2012 -
`Present
`
`KL2 Award, NIH Roadmap
`Multidisciplinary Clinical
`Research Scholar Program
`
`Instructor, Case Western Reserve
`University, School of Engineering,
`
`Myla
`Goldman, MD
`Postdoctoral
`Fellow
`Bennie Jeng,
`MD
`Postdoctoral
`Fellow
`Thomas
`Frazier, PhD
`
`Postdoctoral
`Fellowship
`Michael Fu,
`PhD
`Postdoctoral
`Fellowship
`
`
`
`Selected Presentations:
`
`1.
`
`
`2.
`
`
`3.
`
`
`4.
`
`
`5.
`
`
`6.
`
`
`
`Isolation and ultrastructural characteristics of model soluble immune complexes
`(ICx) using ferritin conjugates of monoclonal anti-human IgG (anti-IgG-F).
`American Federation Clinical Research, 1982, Boston, Massachusetts.
`
`Free light chains in the CSF of patients with multiple sclerosis. American Academy
`of Neurology, 1985, Dallas, Texas.
`
`Free light chains in multiple sclerosis spinal fluid. International Federation of
`Multiple Sclerosis Societies Workshop on Cellular and Humoral Components of
`CSF in Multiple Sclerosis, 1986, Hengelhoef, Belgium.
`
`Antibodies as a disease state marker for multiple sclerosis: optimizing diagnostic
`testing. International Workshop on Diagnostic and Therapeutic Trials in MS, 1988,
`Jekyll Island, Georgia.
`
`Quality of life in multiple sclerosis: Comparison with inflammatory bowel disease
`and rheumatoid arthritis. American Academy of Neurology, 1990, Miami Beach,
`Florida.
`
`Pregnancy in Multiple Sclerosis. Issues Seminar of the National Multiple Sclerosis
`Society, 1990, Miami Beach, Florida.
`
`Page 10
`
`Page 10 of 70
`
`

`

`Curriculum Vitae
`Richard A. Rudick, M.D.
`
`7.
`
`Cognitive impairment in multiple sclerosis: Issues for patient care. International
`Federation of MS Societies, European Charcot Foundation and US National MS
`Society workshop on Neurobehavioral Disorders in Multiple Sclerosis: Diagnosis,
`Underlying Pathology, Natural History and Therapeutic Intervention, 1992,
`Bergamo, Italy.
`
`
`
`
`8.
`
`
`9.
`
`
`10.
`
`
`11.
`
`
`12.
`
`
`13.
`
`
`14.
`
`
`15.
`
`
`16.
`
`
`17.
`
`
`18.
`
`19.
`
`Inhibition of T-cell activation by recombinant interferon ß in multiple sclerosis
`patients, International Society for Interferon Research, 1992, Toronto, Canada.
`
`Biologic Effects of Interferon. Presented at the European Charcot Foundation
`Symposium on Interferon Beta for Multiple Sclerosis, 1994, Brussels, Belgium.
`
`Design of the NIH Phase III Trial of Interferon Beta for Exacerbating Remitting MS.
`Presented at the European Charcot Foundation Symposium on Interferon Beta
`for Multiple Sclerosis, 1994, Brussels, Belgium.
`
`The effects of recombinant human interferon beta on mitogen-driven interferon
`gamma mRNA accumulation in peripheral blood mononuclear cells. Society for
`Experimental Neuropathology Annual Meeting, October 1994, San Francisco,
`California.
`
`Rational basis for multiple sclerosis therapeutics. First Visiting Professor for the
`Western New York Neuroscience Society, April 1995, Buffalo, New York.
`
`Results of a phase III trial of Avonex (interferon ß-1a) for relapsing multiple
`sclerosis. Key Opinion Leader Conference, September 1995, Paris, France.
`
`Pathogenesis of Multiple Sclerosis and Mechanisms of IFNß Efficacy. Presented at
`the annual meeting of the European Committee for Treatment and Research in
`Multiple Sclerosis, September 1995, Jerusalem, Israel.
`
`Clinical outcomes assessment in multiple sclerosis. Presented to the NMSS
`Medical Advisory Board, March 1996, San Francisco, California.
`
`Results of a phase III trial of Avonex (interferon ß-1a) for relapsing multiple
`sclerosis. Presented at the European Charcot Foundation Symposium on IFNß-1a,
`April, 1996, Brussels, Belgium.
`
`Treatment of MS patients with type I interferon. Presented at the 12th Annual
`Meeting of the European Committee for Treatment and Research in Multiple
`Sclerosis, September 1996, Copenhagen, Denmark.
`
`Results of a phase III trial of Avonex (interferon ß-1a) for relapsing multiple
`sclerosis. Key Opinion Leader Conference, September 1996, Copenhagen,
`Denmark.
`Clinical outcomes assessment in multiple sclerosis. Presented at the 1st Annual
`Meeting of the American Committee for Treatment and Research in Multiple
`
`Page 11
`
`Page 11 of 70
`
`

`

`Curriculum Vitae
`Richard A. Rudick, M.D.
`
`
`Sclerosis, December 1996, Miami, Florida.
`
`
`
`
`20.
`
`
`21.
`
`
`22.
`
`
`23.
`
`
`24.
`
`
`25.
`
`
`26.
`
`
`27.
`
`
`28.
`
`
`29.
`
`
`30.
`
`
`31.
`
`Avonex for relapsing multiple sclerosis. Presented at a symposium: Controversies
`in the management of relapsing multiple sclerosis, March 1997, Calgary, Alberta,
`Canada.
`
`Interferon therapy for relapsing remitting MS. Presented at a symposium
`sponsored by Astra: Multiple sclerosis - from pathogenesis to therapy. March
`1997, Stockholm, Sweden.
`
`Significance of neutralizing antibodies to Avonex in relapsing multiple sclerosis.
`Platform presentation at the American Academy of Neurology, April 1997,
`Boston, Massachusetts.
`
`Cytokine changes with IFNß-1a (Avonex) treatment: Results from controlled
`clinical trials. Presented at the 13th annual meeting of the European Committee
`for Treatment and Research in MS, November 5, 1997, Istanbul, Turkey.
`
`Emerging concepts on MS pathogenesis. Neurology Grand Rounds. Johns
`Hopkins School of Medicine, November 20, 1997, Baltimore, Maryland.
`
`Axonal transection in multiple sclerosis and its therapeutic implications. Presented
`at the Gordon Conference on Myelin, February 2, 1998, Ventura, California.
`
`Cytokine fluctuations in multiple sclerosis. Presented at the International
`workshop on Th1/Th2 T cell differentiation in MS and Autoimmunity, April 4, 1998,
`Savannah, Georgia.
`
`Emerging concepts on MS pathogenesis. Presented at Neurology Grand Rounds.
`University of Rochester School of Medicine, April 10, 1998, Rochester, New York.
`
`Emerging concepts on MS pathogenesis and their relationship to therapy.
`Charcot Lecture, National Multiple Sclerosis Society, May 13, 1998, Washington,
`D.C.
`
`A 29-year-old with recently diagnosed multiple sclerosis. Presented at the JAMA
`Clinical Crossroads Neurology Grand Rounds, Beth Israel Deaconess Medical
`Center, Harvard, June 10, 1998, Boston, Massachusetts.
`
`Clinical implications of axonal pathology in MS. Presented at New MS Treatment
`Practices, a symposium at the 14th Congress of the European Committee for
`Treatment and Research in Multiple Sclerosis. Symposium sponsored by
`Astra/Biogen, September 11, 1998, Stockholm, Sweden.
`
`Significance of neutralizing antibodies to interferon beta in MS patients.
`Presented at the Consortium of Multiple Sclerosis Centers (CMSC) Annual
`Meeting, October 1998, Cleveland, Ohio.
`
`Page 12
`
`Page 12 of 70
`
`

`

`Curriculum Vitae
`Richard A. Rudick, M.D.
`
`
`32. Monitoring cerebral atrophy in relapsing-remitting MS patients. Presented at the
`3rd annual meeting of the American Committee for Treatment and Research in
`Multiple Sclerosis (ACTRIMS), October 18, 1998, Montreal, Quebec.
`
`
`
`
`33.
`
`
`34.
`
`
`35.
`
`
`36.
`
`
`37.
`
`
`38.
`
`
`39.
`
`
`40.
`
`
`41.
`
`
`42.
`
`
`43.
`
`
`44.
`
`Emerging concepts of MS pathogenesis and their clinical implications. Presented
`at Neurology Grand Rounds, University of Southern California, January 19, 1999,
`Los Angeles, California.
`
`How good are our treatments for multiple sclerosis? Presented at the Los Angeles
`Society for Neurosciences, January 20, 1999, Los Angeles, California.
`
`Effects of interferon beta on CNS inflammation in patients with multiple sclerosis.
`Presented at the Keystone Symposium on “Effectors of Inflammation in the CNS”,
`March 12, 1999, Taos, New Mexico.
`
`Effects of Avonex (Interferon beta 1a) on brain atrophy in multiple sclerosis.
`Presented at the Biogen Investigator Meeting, April 22, 1999, Toronto, Canada.
`
`Treatment of relapsing remitting multiple sclerosis. Presented at
`Immunosuppressive Treatment in Neurologic Disease, a course at the American
`Academy of Neurology Annual meeting, April 23, 1999, Toronto, Ontario,
`Canada.
`
`Brain atrophy in relapsing-remitting MS. Presented at “The understanding and
`management of MS: Towards the new millennium”, May 8, 1999, Amsterdam, The
`Netherlands.
`
`Brain Atrophy. Invited presentation at the joint ECTRIMS/ACTRIMS Meeting,
`September 16, 1999, Basel, Switzerland.
`
`Use of the brain parenchymal fraction to monitor patients with relapsing remitting
`multiple sclerosis. Presented at Neurology Grand Rounds University of Michigan,
`December 12, 1999, Ann Arbor, Michigan.
`
`Novel approaches to measuring and predicting disease severity in multiple
`sclerosis. Presented at Neurology Grand Rounds, University of Texas Southwest
`Medical Center, January 12, 2000, Dallas, Texas.
`
`Advances in the pathogenesis of multiple sclerosis. Presented at the Iowa
`Midwest Neuroscience Association, March 10, 2000, Iowa City, Iowa.
`
`
`A rationale for early therapy in multiple sclerosis. Presented at the MS Therapy
`Night, a CME course at the American Academy of Neurology Annual Meeting,
`May 30, 2000, San Diego, California.
`
`Interferons and MS. Plenary Session presented at the International Society
`
`Page 13
`
`Page 13 of 70
`
`

`

`Curriculum Vitae
`Richard A. Rudick, M.D.
`
`
`Interferon Cytokine Research, October 11, 2001, Cleveland, Ohio.
`
`
`
`Diagnosis of MS, Presented at the Consortium Multiple Sclerosis Centers
`Consensus Conference, November 30, 2001, Fort Worth, Texas.
`
`Long term benefits of interferon therapy in MS? Presented to the Montreal
`Neurologic Society, March 14, 2002, Montreal, Quebec, Canada.
`
`New measurement techniques in multiple sclerosis, Neuroscience Grand Rounds,
`Montreal Neurological Institute, March 15, 2002, Montreal, Quebec, Canada.
`
`Clinical Research, Keynote Address at the Annual AOA Honors Medical Society,
`March 21, 2002, Buffalo, New York.
`
`The Case for Early Treatment in Clinically Isolated Syndromes and Relapsing-
`Remitting, Presented at MS Therapy night at the American Academy of
`Neurology, April 16, 2002, Denver, Colorado.
`
`
`50. Mentoring Clinical Investigators Promoting Integrity in Clinical Research,
`Presented at a course, the Office of Research Integrity Conference, May 3, 2002,
`Cleveland, Ohio.
`
`
`45.
`
`
`46.
`
`
`47.
`
`
`48.
`
`
`49.
`
`
`51.
`
`
`52.
`
`
`53.
`
`Clinical Scales for Multiple Sclerosis Trials. Presented NMSS International Workshop
`on Brain Repair, October 4, 2002, Nice, France.
`
`Neuroprotection for multiple sclerosis. Presented at the 5th Annual Meeting of the
`American Society for Experimental Neurotherapeutics (ASENT Program), March
`14, 2003 Washington, D.C.
`
`Annual Rate of Whole Brain Atrophy in Multiple Sclerosis: Comparison with
`Healthy Controls. Scientific Platform Presentation, AAN, 55th Annual Meeting,
`March 31, 2003, Honolulu, Hawaii.
`
`
`54. Monitoring patients in neuroprotection clinical trials: Clinical measures.
`Presented at the Nancy Davis Centers Without Walls Annual Meeting, May 9,
`2003, Los Angeles, California.
`
`
`55.
`
`
`56.
`
`
`
`Biological significance of neutralizing antibodies to IFN in multiple sclerosis.
`Presented at the Consortium of MS Centers Workshop on IFN antibodies, May 16,
`2003, London, England.
`
`A study designed to determine the efficacy and safety of natalizumab
`(Antegren) in combination with interferon beta-1a (Avonex) for the treatment of
`relapsing-remitting multiple sclerosis (RRMS). Presented at 19th Congress of the
`European Committee for Treatment and Research in Multiple Sclerosis,
`September 17-20, 2003, Milan, Italy.
`
`Page 14
`
`Page 14 of 70
`
`

`

`Curriculum Vitae
`Richard A. Rudick, M.D.
`
`57.
`
`Current Clinical Issues in MS presented at Neurology Grand Rounds at University
`of Massachusetts Medical Center, November 25, 2003, Boston, Massachusetts.
`
`
`
`
`58.
`
`
`59.
`
`
`60.
`
`
`61.
`
`
`62.
`
`
`63.
`
`
`64.
`
`
`65.
`
`
`66.
`
`
`67.
`
`Clinical and MRI Markers of MS Disease Progression, presented at
`Neurodegeneration and Neuroprotection in Multiple Sclerosis, December 6,
`2003, New York, New York.
`
`Clinical significance of brain atrophy in multiple sclerosis, presented at the
`Annual Meeting of the Consortium of MS Centers, June 4, 2004, Toronto,
`Canada.
`
`Individualizing treatment decisions for patients with relapsing remitting MS.
`Presented at a Biogen dinner conference, June 4, 2004, Toronto, Canada.
`
`Natalizumab for Multiple Sclerosis “New treatments for MS: the role of anti-
`adhesion molecule antibodies”. Presented at the Multiple Sclerosis Conference
`Congress, March 17-18, 2005, Milan, Italy.
`
`Beyond Silos: Future Organization for Clinical Research and for Training Clinical
`Investigators. Presented at the AAMC 2005 Annual Meeting, November 7, 2005,
`Washington, D.C.
`
`Translating Myelin Biology to Disease Models and Patients. Presented at the
`Gordon Research Conference ~Myelin~ 2006, February 16, 2006, Ventura,
`California.
`
`Natalizumab improves health-related quality of life in patients with relapsing
`multiple sclerosis. 58th Annual American Academy of Neurology (AAN) Meeting,
`April 1-8, 2006, San Diego, CA.
`
`Response to Therapy: Biomarkers for Interferon Treatment. 11th Annual ACTRIMS
`Meeting, October 8, 2006, Madrid, Spain.
`
`3 Decades of MS Research: What have we learned, where are we going. NMSS –
`National Board of Directors Meeting / January 16, 2007; San Francisco, CA.
`
`Atrophy in MS: What does it mean? Post Graduate Weekend – Biogen Idec
`Australia, March 26-April 1, 2007; Gold